VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

PRICE: 0 CENTS

Wednesday, December 31, 2025

Intuitive Surgical, Inc.

ISRG · NASDAQ

Market cap (USD)
SectorHealthcare
CountryUS
Data as of
Moat score
83/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Intuitive Surgical provides robotic-assisted surgery platforms (da Vinci for soft-tissue surgery and Ion for endoluminal procedures) and monetizes a large installed base through proprietary instruments and accessories used per procedure and service contracts. Although the company reports a single operating segment, this record is segmented by its disclosed revenue categories: Systems, Instruments and Accessories, and Services. The core moat is ecosystem- and switching-cost-driven: systems, consumables, learning and training, service infrastructure, and digital tools reinforce adoption and ongoing usage. Key risks include intensifying competition from well-capitalized medtech entrants, policy and regulatory shifts that enable third-party servicing or consumables, and hospital cost pressure (including reprocessing and remanufacturing).

Primary segment

Instruments and Accessories

Market structure

Monopoly

Market share

HHI:

Coverage

3 segments · 8 tags

Updated 2025-12-30

Segments

Systems

Robotic-assisted surgical systems for minimally invasive soft-tissue and endoluminal procedures

Revenue

23.5%

Structure

Quasi-Monopoly

Pricing

moderate

Share

Peers

MDTJNJSYKZBH+2

Instruments and Accessories

Proprietary robotic surgery instruments, accessories, and consumables used per procedure on the da Vinci (and Ion) installed base

Revenue

60.8%

Structure

Monopoly

Pricing

strong

Share

Peers

MDTJNJSYKSNN+1

Services

Service contracts, maintenance, and uptime and monitoring services for the da Vinci and Ion installed base

Revenue

15.6%

Structure

Monopoly

Pricing

moderate

Share

Peers

MDTJNJSYKSNN+1

Moat Claims

Systems

Robotic-assisted surgical systems for minimally invasive soft-tissue and endoluminal procedures

Revenue share computed from FY2024 disaggregated revenue: Systems $1.966B of total $8.3521B.

Quasi-Monopoly

Capex Knowhow Scale

Supply

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 2 evidence

High system ASPs plus a large, expanding installed base provide scale to fund R&D, clinical support, and manufacturing and regulatory capability, reinforcing leadership in complex surgical robotics.

Erosion risks

  • Well-capitalized entrants scale deployments (e.g., Medtronic, Johnson & Johnson)
  • China-local competitors gain share via pricing and local preference policies
  • Capital budget constraints shift buyers to lower-cost or subscription models

Leading indicators

  • Annual system placements and installed base growth
  • Average selling price and mix (e.g., da Vinci 5 vs Xi/X/SP)
  • Competitor regulatory approvals and commercial launches

Counterarguments

  • Large medtech incumbents can invest heavily and narrow technical gaps
  • Hospital capital committees can force competitive bids that compress margins

Training Org Change Costs

Demand

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 2 evidence

Role-based training pathways and simulation tools (with tracking) raise organizational adoption and switching costs for surgeons, residents, and OR teams.

Erosion risks

  • Surgeons increasingly train on multiple vendors (multi-homing)
  • Standardized credentialing and third-party training reduces differentiation
  • Remote proctoring lowers the friction of switching platforms

Leading indicators

  • Utilization of Intuitive Learning / SimNow platforms
  • Adoption speed for new system generations at existing sites
  • Share of procedures from newly trained surgeons

Counterarguments

  • Hospitals regularly retrain staff and may switch if ROI is compelling
  • Newer surgeons may be less loyal to a single platform over their careers

Ecosystem Complements

Network

Strength: 5/5 · Durability: durable · Confidence: 4/5 · 1 evidence

A connected ecosystem (systems + instruments/accessories + learning + services + digital insights) increases platform utility and reinforces purchasing and usage around Intuitive workflows.

Erosion risks

  • Regulatory or policy changes weaken closed-ecosystem economics (service/instrument unbundling)
  • Competitors build rival ecosystems with comparable digital tools and training
  • Interoperability standards or third-party components reduce complement lock-in

Leading indicators

  • Recurring revenue share (instruments/accessories + services)
  • Attach rates of new instruments, stapling/energy tools, and digital modules
  • Growth of installed base utilization (procedures per system)

Counterarguments

  • Hospitals can mix vendors across service lines; ecosystem benefits may not justify premium pricing
  • Alternative modalities (laparoscopy/open, drugs) can reduce procedure demand in some indications

Procurement Inertia

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Lengthy capital procurement and approval processes can favor incumbents with existing relationships, references, and validated program economics.

Erosion risks

  • Shift to subscription or per-procedure pricing reduces capital barrier for new entrants
  • Hospital budget pressure delays upgrades and new placements

Leading indicators

  • Average sales cycle length and backlog
  • Mix of purchases vs leases or subscription arrangements
  • Average time between system upgrades at existing sites

Counterarguments

  • Long sales cycles also slow Intuitive's own upgrade cycles and can amplify budget-driven delays
  • Group purchasing organizations can force competitive tenders that reduce incumbent advantage

Instruments and Accessories

Proprietary robotic surgery instruments, accessories, and consumables used per procedure on the da Vinci (and Ion) installed base

Revenue share computed from FY2024 disaggregated revenue: Instruments and accessories $5.079B of total $8.3521B.

Monopoly

Installed Base Consumables

Demand

Strength: 5/5 · Durability: durable · Confidence: 5/5 · 2 evidence

Per-procedure instruments and accessories are largely tied to Intuitive platforms and are limited-use, creating a durable recurring revenue stream proportional to procedure volume.

Erosion risks

  • Third-party reprocessing and remanufacturing reduces instrument replacement rates
  • Procedure growth slows or shifts to alternative modalities
  • Pricing pressure from large IDNs and GPOs and hospital cost containment

Leading indicators

  • Instruments and accessories revenue per procedure
  • Global procedure growth and procedure mix by specialty
  • Penetration of reprocessed and third-party instruments (where permitted)

Counterarguments

  • Hospitals can push back on consumables pricing and extend life via reprocessing
  • If competing platforms gain placements, consumables attach can shift away over time

IP Choke Point

Legal

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Platform-specific compatibility plus regulatory requirements constrain unauthorized instruments; third-party counterfeit and remanufactured instruments are cited as a risk, implying Intuitive's proprietary interface and control is economically meaningful.

Erosion risks

  • Regulators clear third-party remanufactured instruments for newer systems
  • Policy pushes for interoperability or right-to-repair style access
  • Customer acceptance of third-party substitutes increases

Leading indicators

  • FDA and CE clearances for third-party remanufactured instruments
  • Litigation and enforcement outcomes related to counterfeits or IP
  • Gross margin trend in instruments and accessories

Counterarguments

  • If third-party instrument ecosystems become approved and trusted, the choke point weakens
  • Hospitals may prioritize cost reduction over OEM-only consumables where clinically acceptable

Services

Service contracts, maintenance, and uptime and monitoring services for the da Vinci and Ion installed base

Revenue share computed from FY2024 disaggregated revenue: Services $1.3071B of total $8.3521B.

Monopoly

Service Field Network

Supply

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence

A dense field service network plus 24/7 support and proactive monitoring supports high uptime and reinforces service renewals for mission-critical OR equipment.

Erosion risks

  • Third-party service providers compete on price or coverage
  • Right-to-repair and parts access regulation expands
  • Cybersecurity incidents disrupt connected monitoring

Leading indicators

  • Service contract renewal and attach rates
  • System uptime and unplanned downtime incidence
  • Service gross margin and cost-to-serve trends

Counterarguments

  • Large hospital systems may build in-house biomedical engineering capacity or use third parties
  • Competitors can bundle aggressive service terms with new system placements

Data Workflow Lockin

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 2 evidence

Connected systems and a customer portal (utilization analytics, orders, maintenance history) embed Intuitive data and services into hospital operational workflows.

Erosion risks

  • Hospitals demand data portability and integrate analytics into internal BI stacks
  • Privacy and security regulation constrains data sharing and cloud features
  • Competitors provide comparable analytics and remote monitoring

Leading indicators

  • Adoption of portal and analytics tools (e.g., user seats, logins)
  • Depth of integration (APIs, data exports) and customer retention
  • Cybersecurity events and regulatory enforcement impacting data use

Counterarguments

  • Hospitals can replace OEM analytics with internal tools; workflow lock-in may be modest
  • Data features can become table stakes and reduce differentiation

Long Term Contracts

Demand

Strength: 3/5 · Durability: medium · Confidence: 4/5 · 2 evidence

Service contracts are typically attached at system purchase and renew over time; Intuitive states that substantially all customers have historically sourced service from Intuitive.

Erosion risks

  • Customers rebid service at renewal and renegotiate fees
  • Third-party service offerings mature and gain trust
  • Policy and legal changes require parts and tooling access for independent service

Leading indicators

  • Service contract renewal rates and pricing
  • Share of service revenue from contract vs time-and-materials
  • Incidence of third-party service usage

Counterarguments

  • Service can be unbundled if third parties become viable and parts access expands
  • Large customers may have leverage to compress service fees over time

Evidence

sec_filing
Intuitive Surgical, Inc. Form 10-K (FY ended Dec 31, 2024) - Business model (system pricing)

Our da Vinci surgical systems sell for between $0.7 million and $3.1 million.

Indicates high capital intensity and price point for system purchases.

sec_filing
Intuitive Surgical, Inc. Form 10-K (FY ended Dec 31, 2024) - Installed base

As of December 31, 2024, we had an installed base of 9,902 da Vinci surgical systems and 805 Ion endoluminal systems.

Installed base scale supports learning effects, service density, and recurring monetization.

sec_filing
Intuitive Surgical, Inc. Form 10-K (FY ended Dec 31, 2024) - Learning technology (Intuitive Learning)

Intuitive Learning enables customers to complete technology and procedure education, while also being able to view, assign, and track learning offerings,

Shows structured training offerings embedded in adoption.

sec_filing
Intuitive Surgical, Inc. Form 10-K (FY ended Dec 31, 2024) - Learning technology (SimNow tracking)

The SimNow online connection drives real-time simulation performance tracking and provides the ability for our customers to use analytics

Training with measurable progression and analytics increases organizational stickiness.

sec_filing
Intuitive Surgical, Inc. Form 10-K (FY ended Dec 31, 2024) - Segment information (ecosystem)

This connected ecosystem includes systems, instruments and accessories, learning, and services connected by a digital portfolio of insights, apps, and services

Company explicitly frames the offering as an integrated ecosystem, supporting complement-driven moat.

Showing 5 of 14 sources.

Risks & Indicators

Erosion risks

  • Well-capitalized entrants scale deployments (e.g., Medtronic, Johnson & Johnson)
  • China-local competitors gain share via pricing and local preference policies
  • Capital budget constraints shift buyers to lower-cost or subscription models
  • Surgeons increasingly train on multiple vendors (multi-homing)
  • Standardized credentialing and third-party training reduces differentiation
  • Remote proctoring lowers the friction of switching platforms

Leading indicators

  • Annual system placements and installed base growth
  • Average selling price and mix (e.g., da Vinci 5 vs Xi/X/SP)
  • Competitor regulatory approvals and commercial launches
  • Systems gross margin trend
  • Utilization of Intuitive Learning / SimNow platforms
  • Adoption speed for new system generations at existing sites
Created 2025-12-30
Updated 2025-12-30

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.